Haleon plc (NYSE:HLN) Stake Boosted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 0.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,630,307 shares of the company's stock after purchasing an additional 58,444 shares during the quarter. Envestnet Asset Management Inc. owned about 0.17% of Haleon worth $72,793,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Sierra Ocean LLC acquired a new stake in shares of Haleon in the 4th quarter valued at $26,000. Versant Capital Management Inc lifted its stake in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Haleon during the fourth quarter worth about $35,000. Toronto Dominion Bank raised its stake in Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock valued at $38,000 after acquiring an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the fourth quarter worth $39,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Trading Up 0.3 %

Shares of NYSE HLN traded up $0.04 during midday trading on Tuesday, hitting $10.15. The stock had a trading volume of 8,420,997 shares, compared to its average volume of 7,011,333. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $8.03 and a 1-year high of $10.80. The company has a fifty day moving average price of $10.05 and a 200 day moving average price of $9.81. The company has a market capitalization of $45.83 billion, a price-to-earnings ratio of 29.87, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio (DPR) is 58.97%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HLN. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. HSBC reissued a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Six analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.